EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serabelisib, a Selective PI3Kα Inhibitor, for Slow-Flow Vascular Malformations in a Phase 3 Multicenter Single-Arm Study with Natural History Comparison

Noriko Aramaki-Hattori, Satoru Sasaki, Naoki Murao, Taiki Nozaki, Akihiro Fujino iD, Ayato Hayashi, Michio Ozeki, Saori Endo, Shimpei Akiyama, Tadashi Nomura iD, Shunsuke Sakakibara iD, Yoshihisa Kawakami iD und 4 weitere

Journal of Clinical Medicine · 05.11.2026 · 15 (21) · 8624

DOI: 10.3390/jcm15218624 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Noriko Aramaki-Hattori und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaken Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Slow-flow vascular malformations, including venous malformation (VM), lymphatic malformation (LM), and Klippel–Trenaunay syndrome (KTS), are rare, symptomatic disorders with limited treatment options. This study evaluated the efficacy and safety of serabelisib, an orally available selective phosphoinositide 3-kinase α inhibitor, in these patients. Methods: This phase 3, multicenter, single-arm, confirmatory study was conducted in Japan (September 2023–June 2025). Patients aged ≥2 years received oral serabelisib once daily (100 mg for body weight ≥ 40 kg; 60 mg/m2 for

Schlagwörter

Stichwörter der Autor:innen

Klippel–Trenaunay syndromelymphatic malformationphosphoinositide 3-kinase α inhibitorserabelisibvenous malformation

Autor:innen und Institutionen

  • Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Department of Plastic Surgery, Tonan Hospital, Sapporo 060-0004, Japan.
  • Department of Radiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Department of Pediatric Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Department of Plastic and Reconstructive Surgery, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
  • Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.

ORCID-Profile: Akihiro Fujino, Tadashi Nomura, Shunsuke Sakakibara, Yoshihisa Kawakami, Junko Ochi, Motoki Akamatsu, Sadanori Akita

Förderung

  • Kaken Pharmaceutical Co., Ltd.

Zitieren

APA

Aramaki-Hattori, N., Sasaki, S., Murao, N., Nozaki, T., Fujino, A., Hayashi, A., Ozeki, M., Endo, S., Akiyama, S., Nomura, T., Sakakibara, S., Kawakami, Y., Morita, A., Ochi, J., Akamatsu, M., & Akita, S. (2026). Serabelisib, a Selective PI3Kα Inhibitor, for Slow-Flow Vascular Malformations in a Phase 3 Multicenter Single-Arm Study with Natural History Comparison. Journal of Clinical Medicine, 15(21), 8624. https://doi.org/10.3390/jcm15218624

Vancouver

Aramaki-Hattori N, Sasaki S, Murao N, Nozaki T, Fujino A, Hayashi A, et al. Serabelisib, a Selective PI3Kα Inhibitor, for Slow-Flow Vascular Malformations in a Phase 3 Multicenter Single-Arm Study with Natural History Comparison. Journal of Clinical Medicine. 2026;15(21):8624. doi:10.3390/jcm15218624

BibTeX
@article{AramakiHattori2026,
  author = {Aramaki-Hattori, Noriko and Sasaki, Satoru and Murao, Naoki and Nozaki, Taiki and Fujino, Akihiro and Hayashi, Ayato and Ozeki, Michio and Endo, Saori and Akiyama, Shimpei and Nomura, Tadashi and Sakakibara, Shunsuke and Kawakami, Yoshihisa and Morita, Ai and Ochi, Junko and Akamatsu, Motoki and Akita, Sadanori},
  title = {Serabelisib, a Selective PI3Kα Inhibitor, for Slow-Flow Vascular Malformations in a Phase 3 Multicenter Single-Arm Study with Natural History Comparison},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {21},
  pages = {8624},
  doi = {10.3390/jcm15218624}
}
Kostenlos starten →